Lyell Immunopharma, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Dec 2018 | — | — | $130.3M |
| Dec 2019 | — | — | $96.7M |
| Jun 2020 | — | — | $246.0M |
| Sep 2020 | — | — | $134.4M |
| Dec 2020 | $189.8M | $908.3M | $140.4M |
| Mar 2021 | — | — | $244.4M |
| Jun 2021 | $207.9M | $1.23B | $564.4M |
| Sep 2021 | $211.9M | $1.20B | $393.5M |
| Dec 2021 | $197.6M | $1.13B | $293.8M |
| Mar 2022 | $190.9M | $1.07B | $222.6M |
| Jun 2022 | $153.6M | $1.02B | $205.7M |
| Sep 2022 | $157.2M | $977.3M | $116.3M |
| Dec 2022 | $104.3M | $937.6M | $123.6M |
| Mar 2023 | $96.6M | $880.5M | $109.4M |
| Jun 2023 | $98.5M | $835.4M | $224.4M |
| Sep 2023 | $97.4M | $795.0M | $286.2M |
| Dec 2023 | $95.1M | $750.0M | $145.6M |
| Mar 2024 | $91.1M | $694.2M | $125.7M |
| Jun 2024 | $87.6M | $654.1M | $133.4M |
| Sep 2024 | $88.5M | $619.2M | $100.3M |
| Dec 2024 | $108.0M | $490.9M | $105.6M |
| Mar 2025 | $93.3M | $429.8M | $120.3M |
| Jun 2025 | $86.5M | $385.5M | $98.8M |
| Sep 2025 | $78.8M | $408.0M | $123.6M |
| Dec 2025 | $91.9M | $340.1M | $60.2M |
| Mar 2026 | $77.0M | $350.6M | $90.8M |
| Jun 2026 | $77.3M | $311.2M | $73.0M |